Maze Q3 Loss Widens to $48M, Missing Estimates on R&D Costs
MAZE sits 59% above its 52-week low of $21.95.
Summary
Maze posted a Q3 net loss of $47.97 million, worse than the $46.11 million consensus from 12 analysts, and an operating loss of $51.52 million versus the -$48.98 million expected. The miss came from higher R&D spending as the MZE829 and MZE782 programs advanced, plus higher personnel and professional services costs. The company ended the quarter with $477 million in cash, which it says funds operations into 2029 — so this is a spending-rate miss, not a solvency problem. The pipeline calendar is the real story: HORIZON Phase 2 data for MZE829 is expected in early 2027, Phase 2 CIPheR topline for MZE782 in PKU in 2027, and a Phase 2 CKD trial for MZE782 starts in H1 2027.
At the time of this announcement, MAZE was trading at $34.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $21.95 to $53.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.